What top creators are saying about Thermo Fisher Scientific Inc.(TMO)

Mentioned as an upcoming earnings-calendar item, without an earnings estimate or investment recommendation.

Thermo Fisher was mentioned in an earnings-calendar discussion without stock-specific investment analysis.

Mentioned only as an upcoming earnings report; no company-specific forecast or recommendation was provided.

Appeared in a simulated trading blotter without substantive company analysis.

Presented as an established alternative to Quantum-Si's Proteus; a relevant system is described as costing approximately $1 million and measuring more than 8,000 proteins at a time. No specific recommendation on TMO shares is made.

Demonstrating technical bottoming patterns and early signs of institutional accumulation after an extended bear cycle.

One of the top-bought blue-chip stocks by large funds in Q2.

Signed a $2.3 million letter of intent with Precigenetics involving 11 chips as the beginning of a scoped collaboration.

Traded up aggressively by 6% to 9%, prompting the speaker to consider potential short setups after initial small short testing.

Host plans to look into as comparable to Danaher, no current view.

Partnering with OpenAI as part of its aggressive push into enterprise-sector high-margin contracts.

Diagnostic play expected to benefit from testing scale-up during a health crisis.

Partnering with NVIDIA to use AI to transform drug discovery, which is a significant positive development.